Research
Hormonal
Recent developments in bariatric medicine include novel anti-obesity drugs targeting appetite regulation and energy expenditure.
Practitioners should stay informed about new pharmacological options for obesity management.
StrongSupportsmedium confidence
Recent developments include the introduction of novel anti-obesity drugs with mechanisms targeting appetite regulation and energy expenditure.
Why this rating
The review nature of the paper suggests a comprehensive analysis of existing literature.
Source
Bariatric Medicine: A Comparative Review of Current Trends in Obesity Management
Chinua Onyebuchi et al. · medtigo Journal of Medicine · 2024
DOI 10.63096/medtigo3062250
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →